The Life Sciences team advised NodThera Limited in the completion of the initial closing of its aggregate $55 million (£44 million) Series B equity financing.
NodThera’s lead candidate, NT-0167, is being evaluated in a Phase 1 clinical trial in healthy volunteers. Proceeds from the financing will be used to advance NT-0167 through clinical studies, further progress the development of additional compounds — including brain-penetrant NLRP3 inflammasome inhibitors for central nervous system indications — and continued drug discovery efforts.
NodThera is a biotechnology company developing a new class of potent and selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. Led by an experienced management team, NodThera is leveraging new insights into inflammasome biology and chemistry to build a platform of highly differentiated small molecule NLRP3 inhibitors.
The cross-border, cross-disciplinary Goodwin team was led by Graham Defries, Michael Grainger, Matthew Shelley, Inbar Rauchwerger, Zena Hadjiargyrou, Rob Young, Amy Francis, Bridgette Bolte, Louise de Souza, Sarah Bock, and Richard Matheny.
For more details on the financing, please read the press release.